目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Disease
1.2.2. Treatment
1.2.3. Route of Administration
1.2.4. End Use
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease outlook
2.2.2. Treatment outlook
2.2.3. Route of Administration outlook
2.2.4. End Use outlook
2.2.5. Regional outlook
2.3. Competitive Insights

Chapter 3. Acute Myeloid Leukemia Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of acute myeloid leukemia
3.2.1.2. Advancements in diagnostic techniques
3.2.1.3. Growing investments in R&D techniques
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatment
3.2.2.2. Limited treatment options
3.3. Acute Myeloid Leukemia Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pipeline Analysis

Chapter 4. Acute Myeloid Leukemia Treatment Market: Disease Estimates & Trend Analysis
4.1. Global Acute Myeloid Leukemia Treatment Market: Disease Dashboard
4.2. Global Acute Myeloid Leukemia Treatment Market: Disease Movement Analysis
4.3. Global Acute Myeloid Leukemia Treatment Market by Disease, Revenue
4.4. Myeloblastic Leukemia
4.4.1. Myeloblastic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Myelomonocytic Leukemia
4.5.1. Myelomonocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Promyelocytic Leukemia
4.6.1. Promyelocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Monocytic Leukemia
4.7.1. Monocytic leukemia market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Other Diseases
4.8.1. Other diseases market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Acute Myeloid Leukemia Treatment Market: Treatment Estimates & Trend Analysis
5.1. Global Acute Myeloid Leukemia Treatment Market: Treatment Dashboard
5.2. Global Acute Myeloid Leukemia Treatment Market: Treatment Movement Analysis
5.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, By Treatment, Revenue (USD Million)
5.4. Chemotherapy
5.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Anti-metabolites
5.4.2.1. Anti-metabolites market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Alkylating agents
5.4.3.1. Alkylating agents market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Anthracycline drugs
5.4.4.1. Anthracycline drugs market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Others
5.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Targeted Therapy
5.5.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2. FLT3 inhibitors
5.5.2.1. FLT3 inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2.1.1. Rydapt
5.5.2.1.1.1. Rydapt market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2.1.2. Vanflyta
5.5.2.1.2.1. Vanflyta market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2.1.3. Xospata
5.5.2.1.3.1. Xospata market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3. IDH inhibitors
5.5.3.1. IDH inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3.1.1. Tibsovo
5.5.3.1.1.1. Tibsovo market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3.1.2. Rezlidhia
5.5.3.1.2.1. Rezlidhia market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3.1.3. Idhifa
5.5.3.1.3.1. Idhifa market estimates and forecasts 2018 to 2030 (USD Million)
5.5.4. Mylotarg
5.5.4.1. Mylotarg market estimates and forecasts 2018 to 2030 (USD Million)
5.5.5. BCL-2 inhibitor
5.5.5.1. BCL-2 inhibitor market estimates and forecasts 2018 to 2030 (USD Million)
5.5.5.1.1. Venclexta
5.5.5.1.1.1. Venclexta market estimates and forecasts 2018 to 2030 (USD Million)
5.5.6. Hedgehog pathway inhibitor
5.5.6.1. Hedgehog pathway inhibitor market estimates and forecasts 2018 to 2030 (USD Million)
5.5.6.1.1. Daurismo
5.5.6.1.1.1. Daurismo market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Immunotherapy
5.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
5.6.1.1. Bispecific antibodies
5.6.1.1.1. Bispecific antibodies market estimates and forecasts 2018 to 2030 (USD Million)
5.6.1.2. Antibody-drug conjugates
5.6.1.3. Antibody-drug conjugates market estimates and forecasts 2018 to 2030 (USD Million)
5.6.1.4. Immune checkpoint inhibitors
5.6.1.4.1. Immune checkpoint inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
5.6.1.5. Chimeric antigen receptor (CAR) T-cell therapy
5.6.1.5.1. Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Other Treatments
5.7.1. Other treatments market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Acute Myeloid Leukemia Treatment Market: Route of Administration Estimates & Trend Analysis
6.1. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Dashboard
6.2. Global Acute Myeloid Leukemia Treatment Market: Route of Administration Movement Analysis
6.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
6.4. Parenteral
6.4.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Oral
6.5.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Acute Myeloid Leukemia Treatment Market: End Use Estimates & Trend Analysis
7.1. Global Acute Myeloid Leukemia Treatment Market: End Use Dashboard
7.2. Global Acute Myeloid Leukemia Treatment Market: End Use Movement Analysis
7.3. Global Acute Myeloid Leukemia Treatment Market Estimates and Forecasts by End Use, Revenue (USD Million)
7.4. Hospital and Clinics
7.4.1. Hospital and clinics market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Specialty Centers
7.5.1. Specialty Centers market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Homecare Setting
7.6.1. Homecare setting market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Acute Myeloid Leukemia Treatment Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape
9.1. Company/Competition Categorization
9.2. Vendor Landscape
9.2.1. List of key distributors and channel partners
9.2.2. Key customers
9.2.3. Key company market share analysis, 2023
9.2.4. Astellas Pharma Inc.
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Product benchmarking
9.2.4.4. Strategic initiatives
9.2.5. Bristol Myers Squibb Company
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Product benchmarking
9.2.5.4. Strategic initiatives
9.2.6. Celgene Corporation
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Product benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Daiichi Sankyo Company, Limited
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Product benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Jazz Pharmaceuticals, plc
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Product benchmarking
9.2.8.4. Strategic initiatives
9.2.9. Novartis AG
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Product benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Otsuka Pharmaceuticals Co., Ltd.
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Product benchmarking
9.2.10.4. Strategic initiatives
9.2.11. Pfizer, Inc.
9.2.11.1. Company overview
9.2.11.2. Financial performance
9.2.11.3. Product benchmarking
9.2.11.4. Strategic initiatives
9.2.12. Rigel Pharmaceuticals, Inc.
9.2.12.1. Company overview
9.2.12.2. Financial performance
9.2.12.3. Product benchmarking
9.2.12.4. Strategic initiatives
9.2.13. Merck & Co., Inc.
9.2.13.1. Company overview
9.2.13.2. Financial performance
9.2.13.3. Product benchmarking
9.2.13.4. Strategic initiatives
9.2.14. Sanofi
9.2.14.1. Company overview
9.2.14.2. Financial performance
9.2.14.3. Product
9.2.14.4. Benchmarking
9.2.14.5. Strategic initiatives

List of Tables
Table 1 List of abbreviation
Table 2 North America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
Table 3 North America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 4 North America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 5 North America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 6 North America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 7 U.S. acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 8 U.S. acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 9 U.S. acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 10 U.S. acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 11 Canada acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 12 Canada acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 13 Canada acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 14 Canada acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 15 Mexico acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 16 Mexico acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 17 Mexico acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 18 Mexico acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 19 Europe acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
Table 20 Europe acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 21 Europe acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 22 Europe acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 23 Europe acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 24 Germany acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 25 Germany acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 26 Germany acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 27 Germany acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 28 UK acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 29 UK acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 30 UK acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 31 UK acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 32 France acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 33 France acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 34 France acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 35 France acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 36 Italy acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 37 Italy acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 38 Italy acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 39 Italy acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 40 Spain acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 41 Spain acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 42 Spain acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 43 Spain acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 44 Denmark acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 45 Denmark acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 46 Denmark acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 47 Denmark Acute Myeloid Leukemia Treatment market, by end use, 2018 - 2030 (USD Million)
Table 48 Sweden acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 49 Sweden acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 50 Sweden acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 51 Sweden acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 52 Norway acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 53 Norway acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 54 Norway acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 55 Norway acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 56 Asia Pacific acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
Table 57 Asia Pacific acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 58 Asia Pacific acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 59 Asia Pacific acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 60 Asia Pacific acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 61 China acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 62 China acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 63 China acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 64 China acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 65 Japan acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 66 Japan acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 67 Japan acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 68 Japan acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 69 India acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 70 India acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 71 India acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 72 India acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 73 South Korea acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 74 South Korea acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 75 South Korea acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 76 South Korea acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 77 Australia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 78 Australia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 79 Australia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 80 Australia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 81 Thailand acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 82 Thailand acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 83 Thailand acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 84 Thailand acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 85 Latin America acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
Table 86 Latin America acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 87 Latin America acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 88 Latin America acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 89 Latin America acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 90 Brazil acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 91 Brazil acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 92 Brazil acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 93 Brazil acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 94 Argentina acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 95 Argentina acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 96 Argentina acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 97 Argentina acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 98 MEA acute myeloid leukemia treatment market, by region, 2018 - 2030 (USD Million)
Table 99 MEA acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 100 MEA acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 101 MEA acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 102 MEA acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 103 South Africa acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 104 South Africa acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 105 South Africa acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 106 South Africa acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 110 Saudi Arabia acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 111 UAE acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 112 UAE acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 113 UAE acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 114 UAE acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)
Table 115 Kuwait acute myeloid leukemia treatment market, by disease, 2018 - 2030 (USD Million)
Table 116 Kuwait acute myeloid leukemia treatment market, by treatment, 2018 - 2030 (USD Million)
Table 117 Kuwait acute myeloid leukemia treatment market, by route of administration, 2018 - 2030 (USD Million)
Table 118 Kuwait acute myeloid leukemia treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Acute myeloid leukemia treatment market: market outlook
Fig. 14 Acute myeloid leukemia treatment competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Acute myeloid leukemia treatment market driver impact
Fig. 18 Acute myeloid leukemia treatment market restraint impact
Fig. 19 Acute myeloid leukemia treatment market: disease movement analysis
Fig. 20 Acute myeloid leukemia treatment market: disease outlook and key takeaways
Fig. 21 Myeloblastic leukemia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Myelomonocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Promyelocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Postpartum post-traumatic stress disorder (PTSD) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Monocytic leukemia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Other diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Acute myeloid leukemia treatment market: Treatment movement analysis
Fig. 28 Acute myeloid leukemia treatment market: Treatment outlook and key takeaways
Fig. 29 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Anti-metabolites market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Alkylating agents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Anthracycline drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 FLT3 inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Rydapt market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Vanflyta market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Xospata market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 IDH inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Tibsovo market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Rezlidhia market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Idhifa market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Mylotarg market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 BCL-2 inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Venclexta market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Hedgehog pathway inhibitor market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Daurismo market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Bispecific antibodies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Antibody-drug conjugates market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Immune checkpoint inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 52 Chimeric antigen receptor (CAR) T-cell therapy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Other treatments market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 54 Acute myeloid leukemia treatment market: Route of administration movement analysis
Fig. 55 Acute myeloid leukemia treatment market: Route of administration outlook and key takeaways
Fig. 56 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 58 Acute myeloid leukemia treatment market: End Use movement analysis
Fig. 59 Acute myeloid leukemia treatment market: End Use outlook and key takeaways
Fig. 60 Hospital and clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Specialty centers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 Homecare setting market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 63 Ambulatory care centers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 Global acute myeloid leukemia treatment market: Regional movement analysis
Fig. 65 Global acute myeloid leukemia treatment market: Regional outlook and key takeaways
Fig. 66 Global acute myeloid leukemia treatment market share and leading players
Fig. 67 North America, by country
Fig. 68 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 U.S. key country dynamics
Fig. 70 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Canada key country dynamics
Fig. 72 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Mexico key country dynamics
Fig. 74 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 UK key country dynamics
Fig. 77 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 78 Germany key country dynamics
Fig. 79 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 France key country dynamics
Fig. 81 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Italy key country dynamics
Fig. 83 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Spain key country dynamics
Fig. 85 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Denmark key country dynamics
Fig. 87 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Sweden key country dynamics
Fig. 89 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Norway key country dynamics
Fig. 91 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 China key country dynamics
Fig. 94 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Japan key country dynamics
Fig. 96 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 India key country dynamics
Fig. 98 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 99 Thailand key country dynamics
Fig. 100 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 101 South Korea key country dynamics
Fig. 102 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 103 Australia key country dynamics
Fig. 104 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 105 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 106 Brazil key country dynamics
Fig. 107 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 108 Argentina key country dynamics
Fig. 109 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 110 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 111 South Africa key country dynamics
Fig. 112 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 113 Saudi Arabia key country dynamics
Fig. 114 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 115 UAE key country dynamics
Fig. 116 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 117 Kuwait key country dynamics
Fig. 118 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 119 Market share of key market players- acute myeloid leukemia treatment market